Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Metadata
Title
[F-18]-Fluorodeoxyglucose PET and PET-CT in diagnostic imaging evaluation of locally recurrent and metastatic bladder transitional cell carcinoma
Authors
Hossein Jadvar
Vicki Quan
Robert W. Henderson
Peter S. Conti
Publication date
01-02-2008
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 1/2008
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-007-0720-8

Other articles of this Issue 1/2008

International Journal of Clinical Oncology 1/2008 Go to the issue

Review Article

Significance of irradiation in breast-conserving treatment: comparison of local recurrence rates in irradiated and nonirradiated groups

Original Article

Treatment outcomes and dose-volume histogram analysis of simultaneous integrated boost method for malignant gliomas using intensity-modulated radiotherapy

Case Report

Growing teratoma syndrome of ovary

Original Article

Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer

Introduction to Review Articles

Current topics in breast cancer clinical research, 2007

Case Report

Retroperitoneal mature teratoma after orchidectomy for a stage IB pure embryonal testicular carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits